Insulet Corporation $PODD Shares Sold by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS lowered its position in shares of Insulet Corporation (NASDAQ:PODD) by 2.0% in the second quarter, HoldingsChannel.com reports. The fund owned 24,600 shares of the medical instruments supplier’s stock after selling 500 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Insulet were worth $7,729,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT acquired a new stake in Insulet during the 1st quarter worth about $26,000. Larson Financial Group LLC lifted its position in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 81 shares during the period. SouthState Corp lifted its position in Insulet by 253.3% during the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 76 shares during the period. Kozak & Associates Inc. acquired a new stake in Insulet during the 2nd quarter worth about $32,000. Finally, Ramirez Asset Management Inc. acquired a new stake in Insulet during the 1st quarter worth about $53,000.

Insider Activity

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Price Performance

Shares of Insulet stock opened at $320.38 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a twelve month low of $226.50 and a twelve month high of $353.50. The business has a 50-day moving average price of $323.15 and a 200 day moving average price of $299.83. The firm has a market cap of $22.55 billion, a PE ratio of 97.38, a P/E/G ratio of 2.62 and a beta of 1.40.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the previous year, the business earned $0.55 EPS. Insulet’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

PODD has been the subject of several analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Wednesday. Jefferies Financial Group reissued a “buy” rating on shares of Insulet in a report on Thursday, August 7th. Piper Sandler boosted their price objective on Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Rothschild & Co Redburn boosted their price objective on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a report on Friday, October 3rd. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $346.83.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.